Mendus has announced that the first patient has been enrolled in the Phase II AMLM22-CADENCE trial, sponsored by the Australasian Leukaemia and Lymphoma Group. The trial is a multicentre, randomised controlled study testing vididencel in combination with the standard-of-care oral azacitidine versus ...Den vollständigen Artikel lesen ...
© 2025 Edison Investment Research